Harrow, Inc. (HROW) vs Pacira BioSciences, Inc. (PCRX)
- Harrow, Inc. HROW 27.28 −5.11%
- Pacira BioSciences, Inc. PCRX 36.35 +0.06%
Harrow, Inc. and Pacira BioSciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Pacira BioSciences, Inc. is the larger, with a market value of $1.5B against $1.1B — 1.3× the size. Harrow, Inc. has negative trailing earnings, so its P/E is not meaningful; Pacira BioSciences, Inc. trades at 104×. Harrow, Inc. grew revenue faster over the last twelve months: 21.1% against 5.71%. Pacira BioSciences, Inc. has the higher net margin (1.96% vs −13.5%) and the higher return on invested capital (1.58% vs −0.77%). Across the 20 metrics below, Pacira BioSciences, Inc. leads on 17 and Harrow, Inc. on 3.
Valuation
Profitability
| Metric | HROW | PCRX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 73.28% | 79.21% | 53.94% |
| Operating margin | (1.00%) | 2.66% | 0.00% |
| Net margin | (13.51%) | 1.96% | 0.00% |
| Free cash flow margin | (4.75%) | 24.06% | 0.00% |
| Return on equity | (116.07%) | 2.05% | (0.40%) |
| Return on assets | (9.77%) | 1.05% | (3.32%) |
| Return on invested capital | (0.77%) | 1.58% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack